Phase I and II clinical trials of NIR-PIT in patients with recurrent head and neck cancer (HNC), in which anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) conjugated to IR700 (Cetuximab-IR700) was used, showed a tolerable safety profile and promising preliminary efficacy [14]. The gene discussed is EGFR; the disease is head and neck cancer.